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Since 1959, cadaveric vertebral bod-
ies (VB) have been recognized as a po-
tential source of bone marrow for trans-
plantation, when Ferrebee et aI, reported 
for the first time a method of harvesting 
bone marrow cells directly from VB 
obtained during autopsy.! Their method, 
though crude, involved dissociating cells 
from small pieces of marrow by gentle 
chopping and mixing in a stainless steel 
chopper. This process would yield a 
single cell suspension which was subse-
quently collected into a reservoir follow-
ing passage through a 30-mesh filter.! A 
more rapid, simple and economical 
method for obtaining large yields of fat-
free, well dispersed hematopoietic cells 
from the VB was reported by Ray et al 
in 1964.2 This procedure involved com-
pression of surface-sensitized VB in a 
sterile pyrogen-free plastic container. 
The extruded marrow was then homog-
enized, filtered and the fat was removed 
by low speed centrifugation. Addition-
ally, when this marrow was used to treat 
two patients with aplastic anemia, par-
tial clinical and hematological remission 
was seen in only one patient who had 
received five concurrent bone marrow 
transfusions.2 
However, it was not until 1970, that 
Thomas and Storb, by describing their 
novel technique for marrow recovery 
from the iliac crest of live related do-
nors, established the basis for clinical 
bone marrow harvesting that remains in 
use today.3 They addressed several im-
portant issues including anesthesia, sites 
of aspiration, and the preparation of the 
bone marrow ce\l suspension. A conse-
quence of their pioneering work was the 
establishment of allogeneic bone mar-
row transplantation from living related 
donors as a basis for treating severe 
aplastic anemia and certain hematologic 
malignancies. Despite of obvious clini-
cal implications, its therapeutic applica-
tions were limited since HLA matching 
was required to decrease the risks of 
rejection and graft-versus-host-disease 
(GVHD).4.5 The interest in VB bone 
marrow harvesting was, however, re-
kindled in 1984, when Sharp et al de-
scribed a unique method for surgical 
harvesting of cadaveric VB with subse-
quent bone marrow isolation.6 They re-
affirmed the importance of VB as a re-
liable source of nucleated bone marrow 
cells by emphasizing the higher cell 
yields and the relative ease of harvest-
ing VB at the time of multi-organ pro-
curement, thus making them more fea-
sible than iliac crest as a potential source 
of bone marrow from cadaveric donors. 
Furthermore, they also postulated that 
marrow from cadaveric VB by contain-
ing fewer mature T cells, would be less 
likely to induce lethal GVHD, than that 
harvested from the iliac crest of live 
donors, which is routinely contaminated 
by blood-borne mature lymphocytes.7•s 
The concept of actively acquired tol-
erance to whole organ allografts follow-
ing donor bone marrow infusion was first 
conceived by Billingham, Brent and 
Medawar.9 This idea was further ex-
tended by Slavin and StroberlO•lI who 
demonstrated stable chimerism with sub-
sequent induction of donor-specific tol-
erance in rats, that were conditioned 
with fractionated total lymphoid irradia-
tion (TU) prior to bone marrow or 
whole organ transplantation. Sachs et aI, 
using similar conditioning protocols, had 
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evidence of stable chimerism in rodents 
that were reconstituted with mixed al-
logeneic and xenogeneic bone mar-
rowJ2,n,14 However, creation of "space" 
by prior conditioning of animals with ra-
diation or other cytoreductive/cyto-
ablative regimens was considered an 
obligatory step towards engraftment of 
donor bone marrow cells, Similar donor-
specific hypo-responsivcncss was also in-
duced in large animals by infusion of 
bone marrow in irradiated recipients, 
prior to whole organ TX,15-18 
Instead of using host irradiation as 
an imperative prerequisite for subse-
quent donor bone marrow engraftment 
Monaco et al used anti-lymphocyte se-
rum (ALS), for conditioning in recipi-
ents of combined bone marrow and 
whole organ transplants leading to in-
duction of donor-speci fic tolerance. 19-22 
Thomas et al,23,24 using a five-day course 
of rabbit anti-thymocyte globulin [ATG], 
and ribs as a source of marrow, were 
also able to successfully induce trans-
plantation tolerance in primates, which 
in their model was attributed to the 
presence of cells having "veto" function 
in donor bone marrow.25 
However, the last 2 years have seen 
,111 explosion in the field of bone mar-
row and whole organ transplantation, 
triggered by a classical report in Lancet 
by Starzl et al,26 which stressed for the 
first time the importance of donor bone 
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marrow-derived cells in whole organ 
transplantation, and their pivotal role in 
the induction of donor-specific non-re-
activity. The propriety of this paper 
hinged on a key observation that after 
whole organ transplantation, donor cells 
of hematolymphoid origin, migrate out 
of the graft and into the recipient. lead-
ing to the establishment of chimerism, 
which is the first step towards subse-
quent induction of dOllor-specific hypo-
responsiveness.27 This natural and univer-
sal phenomenon of donor cell migration 
after whole organ transplantation and its 
implications in the induction of dOl1or-
specific tolerance, has opened up new 
avenues in pre-clinical and clinical re-
search.28•29 Our experience is based on a 
trial of concomitant donor bone marrow 
and whole organ transplantation with 
infusion of donor bone marrow cells at 
the time of whole organ transplantation, 
without prior conditioning of the recipi-
ent. This chapter reviews the procure-
ment of cadaveric VB from 50 donors 
and its use as a source of donor bone 
marrow. It also details the surface 
phenotyping of bone marrow cells iso-
lated from cadaveric VB. 
PROCUREMENT OF CADAVERIC 
VERTEBRAL BODIES 
All the donors were obtained through 
the Center for Organ Recovery and Edu-
cation (CORE). The surgical technique 
for multi-organ harvesting has been de-
scribed previously.30 After all the solid 
organs have been retrieved, the surgical 
field is prepared for the resection of the 
vertebral column (VC) (fig. Ill.I). The 
protocol employed to harvest VB is a 
modification of an earlier technique 
described by Strong et al,31 and all in-
struments and solutions utilized are 
listed in the Appendix I and II. The 
abdominal and thoracic cavities are as-
pirated and in order to expose the VC, 
bowel, mesentery, diaphragm, lungs, 
esophagus and other soft tissues are dis-
placed. The psoas muscle is dissected 
free of bone by scalpel and the interver-
tebral discs are identified. A straight 
wide Lambotte osteotome is inserted 
using manual pressure between the LS-
Sl interspace (Fig. H1.2), and the VC is 
retracted using the anterior face of Sl 
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as a fulcrum. The posterior interverte-
bral articulation is then dissociated us-
ing a curved osteotome and mallet. The 
paravertebral muscles are dissected free 
of the column, and kept on traction by 
means of an osteotome. The posterior 
interspinal ligaments are then severed 
and a cloth towel is i I1serLed around S 1, 
displacing the osteotome. Using the cloth 
towel for traction, the entire column is 
retrieved. and curved osteotome and 
mallet are used to separate the trans-
verse processes and ribs from the VC 
(Fig. H1.3). The extent of VC resection 
however, depends on the number of 
bone marrow cells required. This proce-
dure makes it possible to resect the 
entire thoracic and lumbar VC en-bloc 
(Fig. H1.4), in approximately 20 minutes. 
The resected VC is then processed 
on a previously prepared back table, 
which contains among other things, one 
large basin, forceps, scalpels, scissors, 
mallet, osteotome and three plastic one-
liter Nalgene jars. The VC is placed on 
a cloth towel, cleared of all the remain-
ing soft tissue, and split through the in-
tervertebral discs into three or four sec-
tions. 1t is then washed inl 0% betadine 
followed by a final rinse in sterile saline 
solution, air dried and placed in Na\gene 
jars containing "harvesting solution" [see 
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appendix II]. The processed VC is trans-
ported at room temperature back to the 
laboratory for bone marrow cell isola-
tion. 
ISOLATION OF BONE MARROW 
CELLS 
Bone marrow cell isolation is carried 
out in a c1ass-1000 clean room facility 
equipped with c1ass-JOO safety cabinets. 
The laboratory set-up for cell isolation 
is described in Appendix J. Employing 
aseptic techniques, the VC is separated 
into individual vertebra, divided along 
the sagittal cranio-caudal axis (Fig. 
H1.5), and placed in the processing 
medium [Appendix II). Using large 
Rongeur, the soft tissue (intervertebral 
disc and the periosteum) is removed. 
The cancellous bone was chipped-off 
piecemeal by small Rongeur and placed 
in the processing medium (Fig. H1.6), 
for passive release of the majority of 
bone marrow cells. This cell suspension 
is then filtered through two consecutive 
stainless steel screens (450 and 180 11m 
respectively), centrifuged at 300g for 10 
minutes, and the cell pellet is resus-
pended in 300 IllI of "resuspension" so-
lution. To release cells trapped within 
the trabecular framework of the mar-
row, cancellous chips retained on the 
filter are re-processed twice by gentle 
shaking in the processing medium for 
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30 minutes each (Fig. H1.7). The cell 
suspension is then centrifuged and pro-
cessed as mentioned above. Cell count 
and viability are assessed by trypan blue 
exclusion, and the cells are finally resus-
pended at 108 cells mP. Samples for 
progenitor cell assay (CFU), microbial 
surveillance and flow cytometric analy-
sis are retained from the final cell prepa-
ration. The remaining bone marrow cells 
are then either used in clinical trials of 
simultaneous bone marrow and whole 
organ transplantation or cryopreserved 
for future use. 
RESULTS 
CEll YIELD 
Vertebral bodies from 50 cadaveric 
donors have been harvested between 
March 1992 and October 1993. The av-
erage donor age was 30 years and on an 
average nine VB were recovered from 
each donor. Red blood cells [RBC] were 
lysed using 2% acetic acid, and viable 
cell count was determined by the trypan 
blue exclusion technique The average 
cell yield/donor was 5.1 x 1010, giving an 
average cell yieldlVB of 5.7 x 109 (Table 
H1.1). 
FACS® ANALYSIS 
Flow cytometric analysis of isolated 
bone marrow cells was performed using 
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the following Phycoerythrin [PEl or 
Fluorescein isothiocyanate [FlTC]-con-
jugated mouse-a-human primary mono-
clonal antibodies [mJ\b] directed against 
the following cell surface receptors: anti-
leukocyte common antigen [lgG b HLe-l, 
CD45], anti-HLA-DR [lgG2a , MHC class 
II], anti-Leu-M3 [JgG2h , CD14], anti-
Leu-M9 [IgG], CD33], anti-HPCA-l 
[JgGJ, CD34], anti-Leu-14 [IgG2b, CD22], 
anti-Leu-19 [IgG I , CD56], anti-Leu-4 
[IgG\, CD3], anti-Leu-3a [IgG I , CD4] 
and anti-Leu-2a [IgG h CD8]. Isotype-
matched irrelevant mAb were used as 
negative controls. All antibodies were 
purchased from Becton Dickinson, 
Mountain View, Cal. Prior to staining, 
RBC were lysed by resuspending the 
cells in NH4C1 solution [0.83% NH4CI 
and 0.1 % KHCOJ in H20]. 2 x 1()5 cells 
were placed in each well of a 96-well 
microtiter plate [Falcon, Lincoln Park, 
NJ], blocked with 10% goat serum for 
15 min. and washed x2 with washing 
solution [WS; PBS + 1 % FCS + 0.5% 
NaN3] [Gibco, Grand Island, NY]. 20 pi 
of appropriate PE or FITC-conjugated 
primary mAb was added to each well, 
incubated for 30 minutes at 4"C, and 
then washed x2 wit II WS. The cells were 
finally fixed with 1 'X, formaldehyde and 
stored at 4°C until analyzed. 
The samples were analyzed using 
Consort 30 acquisition software on a 
Fluorescence Activated Cell Sorter 
[FACStar, Becton Dickinson, Mountain 
View, CaI.]. An analysis gate was estab-
lished using the forward and orthogonal 
light scatter profile of unstained bone 
marrow cells. Markers to delineate posi-
tive staining were set based on staining 
of bone marrow cells with isotype 
matched irrelevant mAbs. Purity of the 
anlaysis gate was determined by stain-
ing of the bone marrow cells with FITC-
conjugated anti-CD4S and PE-conju-
gated anti-CD14 (Leucogate™, Becton 
Dickinson) 50,000 events were acquired, 
and the expression of appropriate lin-
eage marker evaluated. The phenotype 
of human bone marrow cell is detailed 
in Table H1.2. 
THE ClONOGENIC CELL ASSAYS 
To propagate colony forming units 
[CFU], duplicate samples of 2 x J05 bone 
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Table HT.T. Bone marrow cell yield 
from human vertebral bodies 'VB] 
Number of VB/donor 
Donor age [yr] 
001101 weight [kg] 
Cell yield/donor [xl 0 10] 
Cell yield/VB I x 10"] 
Cell yield/dollor weight [xl OR/kg] 
mean ±SE 
9 ± 0.34 
30±3 
74 ± 5.3 
5.1 ± 4.4 
5.7 ± 0.4 
745.3 
Fig. H 1.7. Isolation oj hone 
marroH'froJ1llzlllllllll vertehral 
bodies. 
Table HI.2. FACS® analysis of the cell surface phenotype of human 
vertebral bone marrow 
Antigen* 
Pan leukocyte 
CD45 
Progenitor cells 
CD33 
CD34 
Monocytes 
CD14 
B cells 
CD22 
NK cells 
CD56 
T cells 
CD3 
CD4 
CD8 
MHC 
HLA-DR 
Positive Events (%) 
Total CD4S-gated 
[mean] [mean ±1 SD] 
38.4 
1.5 ± 0.6 
1.8 ± 0.4 
4.2 ± 1.6 
3.9±1.6 
3.6 ± 1.6 
14.7±4,4 
6.3 ± 2.9 
8 ± 4.2 
10± 1.1 
619 
620 
Table Hl.3. C/onogenic progenitor 
numbers in normal bone marrow from 
cadaveric vertebral bodies 
Colonies 
BFU-E 
DFU-GM 
CFU-GEMM 
mean±SE 
[per 2 x 105 cells] 
92 ± 8_8 
46-4 ± 3-4 
5.9 ± 0.9 
Table Hl.4. Transplantation groups; 
combined donor bone marrow and 
whole organ 
Organs Tx 
Liver 
Liver + Islets 
Kidney 
Kidney + Islets 
Hearl 
Small bowel 
TOTAL 
withTLI 
[nl 
2* 
2 
withoutTLI 
[nl 
5 
1 
7 
2 
17 
* each patient received a single dose of 500 and 
550 cGy of TLI respectively 
marrow cells were plated in 35 mm petri 
dishes in Terry Fox medium [Terry Fox 
Laboratory, Vancouver, B.c., Canada], 
and incubated for 14 days at 37°C in a 
humidified atmosphere of 5% CO2 in 
air. At the end of this incubation pe-
riod, colonies were scored using an in-
verted microscope. 
Under appropriate culture conditions 
[see above], 2 x 105 nucleated bone 
marrow cells yield 92±8.8 burst-forming-
unit erythroid (BPU-E), 46.4 ± 3.4 
colony-forming-unit granulocyte and 
macrophage (CPU-OM), and 5.9 ± 0.9 
colony-forming-unit granulocyte, eryth-
rocyte, macrophage and megakaryocyte 
(CFU-GEMM) Crable H1.3). 
CLINICAL TRANSPLANTATION 
A total of 19 patients have received 
simultaneous donor bone marrow and 
whole organ transplantation between 
June 1992 and October 1993 at the 
University of Pittsburgh Medical Cen-
ter (Table 1-11.4). The first two liver re-
cipients were conditioned with a single 
dose [500 and 550 cOy respectively] of 
total lymphoid irradiation (TLI) prior to 
transplantation. Due to an unfavorable 
clinical outcome in one of these patients, 
prior TLI conditioning regimen was 
abandoned. All subsequent transplants 
were done without any cytoreductive or 
cytoablative conditioning of the recipi-
ents. Autologous bone marrow was 
harvested from the iliac crest of all re-
cipients prior to transplantation and cryo-
preserved, in the event that host immuno-
hematopoietic reconstitution would be 
required. Patients transplanted with 
donor bone marrow and various whole 
organs, without prior conditioning in-
clude; liver [n=5], liver + islets [n=l], 
kidney [n=7], kidney + islets [n=2], heart 
[n=1] and small bowel [n=l]. Immedi-
ately after whole organ transplantation, 
3 x 108 donor bone marrow cells/kg body 
weight of the recipient, were infused 
through a central intravenous line. All 
recipients received routine immuno-
suppression with FK506 and Prednisone. 
The presence of donor cells [chimerism] 
was evaluated in the recipient's peripher-
al blood lymphocytes [PBL], weekly in 
the first month and monthly thereafter. 
For immunohistochemical identification 
of donor cells [by FACS® and cytospins], 
donor and recipient-specific anti-MHC 
class I monoclonal antibodies were used, 
whereas for PCR, donor and recipient-
specific DR-probes were used. In occa-
sional male to female organ recipients 
[n=4], the presence of Y chromosome 
in the recipient was also analyzed by 
PCR and in situ hybridization_ The pre-
transplant and monthly in vitro immune 
status of the recipient was monitored by 
mixed lymphocyte reaction [MLR] and 
cell mediated lymphocytotoxicity [CML] 
assays. Recipients of whole organ trans-
plants alone were also monitored as 
controls. 
Bone marrow infusion was unevent-
ful in all patients, although both of the 
patients who received TLI conditioning 
prior to bone marrow and liver trans-
plantation had a very turbulent post-
operative course. One of them devel-
oped Grade 1II graft-versus-host-disease 
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[GVHD], which necessitated re-infusion 
of cryopreserved autologous bone mar-
roW.32 He subsequently lost all graft func-
tion and had to rescued with a re-trans-
plant. He eventually succumbed from 
complications of intestinal perforation. 
All patients in the 110n-TLI group are 
doing fine and are chimeric. On the 
other hand, donor cells are barely de-
tectable in patients in the control group 
[organ transplant alone] 4 weeks after 
transplantation. A variable degree of 
immunomodulation was also seen in 
patients in the study group, with some 
losing all donor-specific reactivity weeks 
after transplantation, and others main-
taining proliferative response both 
against the donor and third party stimu-
lators months after transplantation. Two 
patients in the non-TLI group developed 
mild asymptomatic skin rash lboth re-
cipients of liver allografts], shown on 
skin biopsy to be a GVI--I reaction. The 
rash was gone in 2-3 weeks without 
additional treatment in one patient, and 
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Methods in Cell Transplantation 
APPENDIX I 
A: EQUIPMENT REQUIRED FOR 
HUMAN VERTEBRAL BODY 
HARVESTING 
• Straight Osteotome [l.25" wideJ 
• Curved Osteotome [1.25" wide] 
• Mallet 
• Scissors 
• Forceps 
• Procurement Solution [lL] 
• Betadine 
• Normal Saline [3L] 
• Sterile Jars [Nalgene] 
• Protective Face Shield 
• Organ Transport Container 
B: BACK TABLE EQUIPMENT 
• Straight Osteoto11le 
• Mallet 
• Scissors 
• Forceps 
• Sterile Jars [Nalgene] 
• Large Basin 
• Sterile Plastic Bags 
Section H: Bone, Cartilage and Muscle 
c: EQUIPMENT FOR BONE MARROW 
ISOLATION 
• Sterile Wraps 
• Large Stainless Steel Basin 
• Medium Stainless Steel Basin 
• Sterile Scalpel Blades 
• One Mallet 
• Straight Osteotome 1 114" 
• Scissors 
• Forceps 
• Sterile Gauze 
• Processing Solution [1L] 
• 10cc Disposable Syringes 
• Needles [16 G] 
• 40 ml Aerobic Culture Bottles 
[Organon Teknika, Durham, NC] 
• 40ml Anaerobic Culture Bottles 
[Organon Teknika, Durham, NC] 
• Protective Face Shield 
D: EQUIPMENT FOR LAMINAR FLOW 
HOOD 
• Sterile Wraps 
• Basins [medium] 
• Rongeurs (2-Largel2-Medium/2-
Small) 
• Sterile Gauze 
• Sterile Jars [Nalgene] 
• Stainless Steel Container 
• Stainless Steel Jars 
• Stainless Steel Sieves [Pore Size 180 
& 425 11m] 
• Stainless Steel Racks For 250ml 
Conical Tubes 
• Sieve Pans 
• Conical Tubes [250ml] 
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APPENDIX II 
SOLUTION 1: PROCUREMENT SOLUTION 
• Dulbecco's Modified Eagle's Medium 
• Human Serum Albumin [25%] 
• Bacitracin [50,000 U] 
• Polymixin B [500,000 UJ 
• Heparin [lOOO U/ml] 
• Hepes Buffer [1M] 
SOLUTION 2: PROCESSING MEDIUM 
• X-Vivo 10* [BioWhittaker, Walkersville, Md.] 
• Human Serum Albumin [25%] 
• Bacitracin [50,000 U] 
• Polymixin B [500,000 U] 
• Heparin [1000 U/ml] 
SOLUTION 3: RESUSPENSION MEDIUM 
• RPMI 164() 
• Human Serum Albumin [25%] 
• Gentamicin (50 mg/ml) 
• Heparin (1000 U/ml) 
• Hepes Buffer [1M] 
* modified 
624 
500ml 
50ml 
5ml 
Sml 
lOml 
12.Sml 
lOOOml 
100ml 
10ml 
lOml 
lOml 
lOOOml 
100ml 
lOml 
lOml 
25ml 
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